Department of Health and Human Services April 24, 2008 – Federal Register Recent Federal Regulation Documents
Results 1 - 7 of 7
Amendment to the Fiscal Year 2009 Service Area Competition-New and Competing Continuation Funding
HRSA is announcing the reissuance of Fiscal Year 2009 Service Area CompetitionNew and Competing Continuation Funding (HRSA Announcement Numbers HRSA-09-095, HRSA-09-096, HRSA-09-097, and HRSA- 09-098). The HRSA Electronic Handbook (EHB) application deadline for project periods beginning in November and December 2008 has been changed and the list of available service areas has been updated. The new EHB application deadline for HRSA-09-095 is May 9, 2008. (The grants.gov application deadline of April 7, 2008 remains the same.) All other requirements of HRSA-09-095 remain the same. Please see the chart on pages 6 and 7 of the guidance for a complete listing of all application deadlines. In addition, corrections to two service areas listed in the Service Area Competition guidance have been made. In Appendix F of the guidance, Bismarck, ND, is incorrectly listed as an available service area in fiscal year (FY) 2009. The correct service area that is currently available in FY 2009 is Beulah, ND. Also, Clay, WV, is incorrectly listed as an available service area in FY 2009. The correct service area that is currently available in FY 2009 is Blacksville, WV. Bismarck, ND and Clay, WV, are not available service areas for the FY 2009 Service Area Competition. For a complete listing of all available service areas for the FY 2009 Service Area Competition funding opportunity, please see Appendix F of the guidance.
Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Commitment Studies; Availability
The Food and Drug Administration (FDA) is required, under the Food and Drug Administration Modernization Act of 1997 (Modernization Act), to report annually in the Federal Register on the status of postmarketing study commitments made by applicants of approved drug and biological products. This is the agency's report on the status of the studies applicants have agreed to or are required to conduct.
Draft Guidance for Industry on Developing Coronary Drug Eluting Stents; Public Workshop
The Food and Drug Administration (FDA) is announcing a public workshop entitled ``Coronary Drug-Eluting Stent (DES) Guidance Document Workshop.'' FDA is cosponsoring the workshop with the Advanced Medical Technology Association (AdvaMed). The purpose of the workshop is to discuss the draft guidance entitled ``Coronary Drug-Eluting Stents: Nonclinical and Clinical Studies'' announced in the Federal Register of March 27, 2008, and its companion document entitled ``Coronary Drug- Eluting Stents-Nonclinical and Clinical Studies (Companion Document)'' (the Companion Document). The workshop intends to solicit additional comments on the issues and questions presented in the draft guidance during the open comment period.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
